Acacia Pharma Group plc (ACPH.BR)

Acacia Pharma Group plc (ACPH.BR) — VMCI valuation read

Acacia Pharma Group plc sits at VMCI 32/100, with the Healthcare sector median at 50. That 19-point spread is the first thing to note on ACPH.BR: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on ACPH.BR are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on ACPH.BR: ACPH.BR trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of -0.5x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

ACPH.BR fell 2.1% over the trailing 7 days, with a +6.1% read on a 30-day basis.